Pipeline
Cellmid’s product development program involves commercialisation opportunities for the Company’s midkine assets in three broad areas:
- Midkine as a diagnostic marker for cancer
- Midkine protein as a therapeutic to treat heart attack (in partnership with Pharmahungary)
- Anti-midkine antibodies to treat inflammatory diseases (in partnership with Antitope)
To view Cellmid’s complete product pipeline, click here
Business Structure
